Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Research analysts at Leerink Partnrs raised their Q2 2024 earnings estimates for shares of Centessa Pharmaceuticals in a note issued to investors on Monday, May 13th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings per share of ($0.41) for the quarter, up from their prior estimate of ($0.49). The consensus estimate for Centessa Pharmaceuticals' current full-year earnings is ($1.83) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals' Q3 2024 earnings at ($0.42) EPS, Q4 2024 earnings at ($0.47) EPS, FY2024 earnings at ($1.68) EPS and FY2025 earnings at ($1.78) EPS.
Separately, BMO Capital Markets restated an "outperform" rating and set a $15.00 price objective on shares of Centessa Pharmaceuticals in a report on Monday, April 1st. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $10.00.
View Our Latest Stock Analysis on CNTA
Centessa Pharmaceuticals Trading Up 1.8 %
Shares of CNTA traded up $0.16 during mid-day trading on Thursday, reaching $8.95. 104,620 shares of the company's stock traded hands, compared to its average volume of 336,884. The company has a debt-to-equity ratio of 0.32, a current ratio of 8.00 and a quick ratio of 8.00. The stock's 50-day moving average is $10.36 and its two-hundred day moving average is $8.80. Centessa Pharmaceuticals has a 12 month low of $3.96 and a 12 month high of $12.45. The stock has a market cap of $901.62 million, a P/E ratio of -6.30 and a beta of 1.44.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06. The firm had revenue of $6.85 million for the quarter.
Insider Transactions at Centessa Pharmaceuticals
In related news, insider Karen M. Anderson sold 51,160 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $11.88, for a total transaction of $607,780.80. Following the transaction, the insider now directly owns 71,525 shares of the company's stock, valued at $849,717. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 11.59% of the company's stock.
Institutional Trading of Centessa Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC purchased a new stake in Centessa Pharmaceuticals during the 1st quarter valued at about $33,923,000. Octagon Capital Advisors LP boosted its holdings in Centessa Pharmaceuticals by 333.2% during the fourth quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company's stock worth $16,398,000 after buying an additional 1,584,500 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in Centessa Pharmaceuticals by 25.8% during the third quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company's stock worth $18,313,000 after buying an additional 580,500 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Centessa Pharmaceuticals by 16.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company's stock valued at $33,427,000 after buying an additional 418,615 shares during the period. Finally, Acuta Capital Partners LLC purchased a new position in Centessa Pharmaceuticals in the third quarter valued at $2,092,000. Hedge funds and other institutional investors own 82.01% of the company's stock.
About Centessa Pharmaceuticals
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.
Featured Articles
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
